Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: A prospective study

JAMA

Volumn 276, Issue 7, 1996, Pages 544-548

  Bostom, Andrew G ^a,d   Cupples, L Adrienne ^b   Jenner, Jennifer L ^c   Ordovas, Jose M ^c   Seman, Leo J ^c   Wilson, Peter W F ^a   Schaefer, Ernst J ^c   Castelli, William P ^a  

^a Framingham Study   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ANGINA PECTORIS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; FOLLOW UP; GLUCOSE INTOLERANCE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SUDDEN DEATH;

EID: 0029740582     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.7.544     Document Type: Article

References (70)

1. Scanu A. Structural and functional polymorphism of lipoprotein(a). Clin Chem. 1995;41:170-172.
2. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
3. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
4. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229-235.
5. Rhoads GG, Dahlen G, Berg K, Morton N, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
6. Sandkamp M, Funke H, Schulte H, et al. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990; 26:20-23.
7. Genest JJ Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoproteins A-I and B and lipoprotein(a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19:792-802.
8. Craig WY, Poulin SE, Forster NR, Neveux LM, Wald NJU, Ledue TB. Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. Clin Chem. 1992;38:550-553.
9. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease in a general population sample of middle-aged men. BMJ. 1990;301:1248-1250.
10. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischemic heart disease: implications for reening. Lancet. 1994;343:75-79.
11. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA. 1994;271:999-1003.
12. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol, and other risk factors. Eur J Clin Invest. 1994;24:444-453.
13. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. Circulation. 1994;90:1688-1695.
14. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
15. Sigurdsson G, Baldursdottir A, Sigvaldsonason H, Agnarsson U, Thorgeirsson G, Sigufsson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.
16. Jauhiainen M, Koskinen P, Enholm C, et al. Lipoprotein(a) and coronary heart disease. Atherosclerosis. 1991;89:59-67.
17. Alfthan G, Pekannen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis. 1994;106:9-19.
18. Schultz JS, Shreffler DC, Harvie NR. Genetic and antigenic studies and partial purification of a human serum lipoprotein carrying the Lp antigenic determinant. Proc Natl Acad Sci U S A. 1968;61: 963-970.
19. Harvie NR, Schultz JS. Studies of Lp-lipoprotein as a quantitative genetic trait. Proc Natl Acad Sci U S A. 1970;66:99-103.
20. Rider AK, Levy RI, Fredrickson DS. 'Sinking' pre-beta lipoprotein and the Lp antigen. Circulation. 1970;42(suppl 3):III-10.
21. Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scand Suppl. 1972;531: 1-29.
22. Frick MH, Dahlen G, Furberg C, Ericson C, Wiljasalo M. Serum pre-beta-1 lipoprotein fraction in coronary atherosclerosis. Acta Med Scand. 1974; 195:337-340.
23. Heiberg A, Berg K. On the relationship between Lp(a) lipoprotein, 'sinking pre-beta lipoprotein,' and inherited hyperbetalipoproteinemia. Clin Genet 1974;5:144-156.
24. Dahlen G, Ramberg UB. Pre-beta-1 lipoprotein and early detection of risk factors for coronary heart disease. Acta Med Scand. 1974;195:341-344.
25. Albers JJ, Hazzard WR. Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids. 1974;9:15-26.
26. Albers JJ, Veneracion G, Cabana G, Warnick R, Hazzard WR. Lp(a) lipoprotein: relationship to sinking pre-beta lipoprotein, hyperlipoproteinemia, and apolipoprotein B. Metabolism. 1975;24:1047-1054.
27. Linden L, Kallberg M, Gustafson A, Dahlen G. Studies on an additional pre-beta lipoprotein, sinking prebeta. I: isolation and characterization. Scand J Clin Lab Invest. 1976;36:51-58.
28. Dahlen G, Frick MH, Berg K, Valle M, Wiljasalo M. Further studies of Lp(a) lipoprotein/pre-beta-1-lipoprotein in patients with coronary heart disease. Clin Genet. 1975;8:183-189.
29. Petek W, Kostner G, Knoetgen U. Immunochemical characterization of the pre-band in lipoprotein electrophoresis. Clin Chim Acta. 1972;38:460-462.
30. Ballantyne D, Jubb JS, Morgan HG, Lawrie TD. Study of the pedigree of a patient with type 3 hyperlipoproteinemia and sinking pre-beta lipoprotein. J Clin Pathol. 1973;26:163-166.
31. Hewitt D, Milner J, Breckenridge C, Maguire G. Heritability of 'sinking' pre-beta lipoprotein level: a twin study. Clin Genet. 1977;11:224-226.
32. Breckenridge WC, Maguire GF. Quantification of sinking pre-beta lipoprotein in human plasma. Clin Biochem. 1981;14:82-86.
33. Hewitt D, Milner J, Owen AR, et al. The inheritance of sinking pre-beta lipoprotein and its relation to the Lp(a) antigen. Clin Genet. 1982;21: 301-308.
34. Rhoads GG, Morton NE, Gulbrandsen CL, Kagan A. Sinking pre-beta lipoprotein and coronary heart disease in Japanese-American men in Hawaii. Am J Epidemiol. 1978;108:350-356.
35. Morton NE, Gulbrandsen CL, Rhoads GG, Kagan A. The Lp lipoprotein in Japanese. Clin Genet. 1978;14:207-212.
36. Avogaro G, Cazzolato G. 'Sinking' lipoprotein in normal, hyperlipoproteinemic, and atherosclerotic patients. Clin Chim Acta. 1975;61:239-246.
37. Pagan A, Kostner G, Braggion M, Ziron L. Relationship between 'sinking pre-beta lipoprotein' (Lp(a) lipoprotein) and age in a family kindred. Gerontology. 1982;28:381-385.
38. Pagan A, Kostner G, Braggion M, et al. Familial study on 'sinking pre-beta,' the Lp(a) lipoprotein, and its relationship with serum lipids, apolipoprotein A-1 and B and clinical atherosclerosis. J Clin Chem Clin Biochem. 1983;21:267-272.
39. Gambert P, Lallement C, Padieu P. Cholesterol gas-liquid chromatographic microassay in serum lipoproteins separated by polyacrylamide gel electrophoresis. Clin Chim Acta. 1980;100:99-105.
40. Walden CE, Wahl PW, Knopp RH, et al. Hyperlipidemia in the Pacific Northwest Bell Telephone Company Health Survey, part 1. Arterioscl. 1983;3:117-124.
41. Kawakami K, Tsukada A, Okubo M, et al. A rapid electrophoretic method for the detection of serum Lp(a) lipoprotein. Clin Chim Acta. 1989; 185:147-156.
42. McNamara JR, Campos H, Adolphson JL, et al. Screening for lipoprotein(a) elevations in plasma and assessment of size heterogeneity using gradient gel electrophoresis. J Lipid Res. 1989;30:747-755.
43. Bruckert E, Truffert J, De Gennes JL, et al. Does electrophoresis reliably screen for high serum lipoprotein Lp(a)? Clin Chim Acta. 1990;188:71-78.
44. Pearson TA, Kwiterovich PO. Sinking pre-beta lipoprotein. Circulation. 1989;80(suppl 2):102. Abstract 0409.
45. Alvarez JJ, Lasuncion MA, Olmos JM, Herrera E. Interindividual variation in the partition of lipoprotein(a) into lipoprotein subfractions. Clin Biochem. 1993;26:399-408.
46. Nauck M, Winkler K, Wittmann C, et al. Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin Chem. 1995;41:731-738.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
48. Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Heart Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; 1987. National Institutes of Health publication 87-2703. Section 34.
49. Feinleib M, Kannel WB, NcNamara PM, Garrison RJ, Castelli WP. The Framingham Offspring Study. Prev Med. 1975;4:518-525.
50. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham offspring study. Circulation. 1993;87:1135-1141.
51. Institute Inc. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute; 1990.
52. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao X-Q, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-1774.
53. Williams RR, Hopkins PN, Hunt SC, et al. Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah, Arch Intern Med. 1990;150:582-588.
54. Genest JJ Jr, Martin-Munley S, McNamara JR, et al. Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
55. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations, J Clin Invest. 1992;90:52-60.
56. Albers JJ, Marcovina SM. Lipoprotein(a) quantification: comparison of methods and strategies for standardization. Curr Opin Lipidol. 1994;5:417-421.
57. Lovejoy K, Bachorik PS. Lp(a) measurements may be unreliable in stored sera. Circulation. 1994; 90(suppl 1):504. Abstract 2714.
58. Hansen PR, Kharazmi A, Jauhiainen M, Enholm C. Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest. 1994;24:497-499.
59. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Circulation. 1995;92:1582-1589.
60. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 1992;360:670-672.
61. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:301-303.
62. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level, J Clin Invest. 1994;93:50-55.
63. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation. 1990;82:897-902.
64. Ezratty A, Simon DI, Loscalzo J. Lipoprotein (a) binds directly to human platelets and attenuates plasminogen binding and activation. Biochemistry. 1993;32:4628-4633.
65. Ridker PM, Hennekens CH. Risk factors for acute thrombosis. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, eds. Primer in Preventive Cardiology. Dallas, Tex: American Heart Association; 1994:205-216.
66. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co Inc; 1986: 86-89.
67. Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood. 1993;82:392-397.
68. Leerink CB, Duif PFCCM, Gimpel JA, Kortlandt W, Bouma BN, van Rijn HJM. Lysine-binding heterogeneity of Lp(a). Thromb Haemost. 1992; 68:185-188.
69. Wagenknecht LE, Craven T, Manolio TA, Winders S, Hulley SB. Trends in cigarette smoking among young adults (1985 to 1992): the CARDIA study. Circulation. 1996;93:635. Abstract P58.
70. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ. Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem. 1994;40:400-403.